Introduction: Maternal cardiac dysfunction as well as abnormal uterine artery (UtA)
| INTRODUC TI ON
Maternal cardiovascular remodeling is a physiological process required to adjust to the needs of the growing uterus, fetus and placenta. During pregnancy, there is a substantial increase in circulating blood volume and cardiac output (CO), and a decrease in systemic vascular resistance (SVR). 1, 2 Passive leg raising (PLR), a maneuver of lifting the legs from the horizontal plane to 45° using a pivotable bed, provides a rapid reversible auto-fluid challenge by increasing venous return to the heart. 3 The homodynamic response to PLR can be used to assess preload reserve and functional hemodynamics. 4, 5 Using this method, we previously showed that pregnant women have a limited preload reserve. 6, 7 Atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) are the most important members of the natriuretic peptide family that are involved in maintaining volume homeostasis and endothelial function. ANP and BNP are of myocardial origin 8 and are known to be produced in response to myocardial wall stress or pressure overload. 9 ProANP and proBNP are the principal storage form of these peptide hormones that are cleaved into the active hormones ANP and BNP and an inactive fragment, N-terminal (Nt)-proANP and Nt-proBNP, respectively. CNP is a paracrine hormone produced by the endothelium in response to vascular stress.
In uncomplicated human pregnancies, ANP and BNP levels are similar or slightly higher compared with the non-pregnant state but remain stable throughout gestation. [10] [11] [12] Maternal plasma CNP is reduced in healthy pregnant women compared with non-pregnant women, and levels tend to fall with advancing gestation. 13 However, increased levels are found in pregnant women who later develop complications such as preeclampsia and/or fetal growth restriction. 14 Levels of all these natriuretic peptides are known to be increased in preeclamptic pregnancies. [14] [15] [16] As the primary basis of their production during pregnancy is similar to that in non-pregnant women, ANP and BNP could be adopted as biomarkers of early cardiac dysfunction or volume overload during pregnancy. Similarly, CNP could be used as a marker of vascular endothelial dysfunction.
Both maternal systemic hemodynamic measurements and natriuretic peptide levels have been used to assess cardiac function in pregnancy. However, the association between maternal cardiovascular hemodynamics and natriuretic peptides has not been elu- Preeclampsia is known to be associated with cardiac dysfunction and remodeling. 19 Some researchers have found elevated natriuretic peptide levels in preeclampsia, 15, 16, 20 and others have reported that asymptomatic cardiac dysfunction may be detected at mid-gestation in women who subsequently develop preeclampsia. 21 Therefore, our secondary objective was to explore differences in maternal functional hemodynamics and natriuretic peptide levels between women those who did not; however, the natriuretic peptide levels were similar in the two groups. Women developing HDP had a significantly higher increase in stroke volume and cardiac output and more reduction in systemic vascular resistance following passive leg raising compared with the reference group. Left cardiac work index, acceleration index and velocity index decreased following passive leg raising in the reference group but increased in women who later developed HDP.
Conclusions:
ProANP correlated with cardiac output and cardiac work, Nt-proBNP with indices of cardiac contractility, and CNP with UtA blood flow and resistance.
None of these natriuretic peptides measured at 22-24 weeks of gestation reflected cardiac preload reserve or predicted development of HDP.
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Key message
In pregnant women, natriuretic peptides measured at 22-24 weeks correlated with some parameters of baseline cardiovascular function but did not reflect preload reserve and did not predict development of hypertensive disorders of pregnancy.
who subsequently develop hypertensive disorders of pregnancy (HDP) and those who do not.
| MATERIAL AND ME THODS
This study was conducted from January 2009 to November 2013.
The primary objective of the study was assessed in a cross-sectional design, and the secondary objective was assessed in a prospective cohort design.
Pregnant women were informed about the study when they were attending the routine ultrasound screening at 17-20 weeks of gestation. Those women who agreed to participate and signed the informed consent were recruited consecutively and an appointment was made at 22-24 weeks of gestation for the evaluation of their cardiovascular function. These women were subsequently followed until delivery. Exclusion criteria were: age <18 years, chronic hypertension, multiple pregnancy, and presence of any major fetal structural or chromosomal abnormalities.
The participating women were examined in a fasting state, in a quiet room with stable temperature maintained at approximately 22°C. Height and weight were measured using an altimeter (Charder Electronic Co., Taichung City, Taiwan) and an electronic scale (Soehnle, Leifheit AG, Nassau, Germany), respectively. The body mass index (BMI) was calculated as weight/height, 2 and the body surface area (BSA) was calculated using the Du Bois formula Preeclampsia was defined as new-onset hypertension with proteinuria (≥1+ on a routine urinalysis or ≥300 mg/24 h) or organ failure.
HDP included both gestational hypertension and preeclampsia.
| Cardiac function and preload reserve
Maternal cardiac function and systemic hemodynamics were investigated using impedance cardiography (ICG; Philips Medical Systems, Androver, MA, USA) as described previously. 6, 7, 23 ICG is a validated noninvasive technique 24 that allows continuous recording and onscreen display of measured parameters. A single investigator (Å.V.)
performed all ICG measurements.
Woman's age, present weight and height were input into the ICG machine, central venous pressure (CVP) was preset at 4 mmHg, and pulmonary artery occlusion pressure (PAOP) was preset at 8 mmHg.
The following variables were continuously displayed on the ICG screen: cardiac output (CO), cardiac index (CI), heart rate (HR), sys- 
| Uterine artery hemodynamics
UtA hemodynamics was assessed by Doppler ultrasonography using an Acuson SEQUOIA 512 ultrasound system (Mountain View, CA, USA). Two experienced operators (C.W. and K.F.) performed all ultrasound examinations following the ALARA (as low as reasonably achievable) principle, 25 using the method described previously.
23,26-28
UtA was identified transabdominally using color Doppler and blood flow velocity waveforms were recorded from the left and right UtA using pulsed-wave Doppler, keeping the insonation angle as low as possible (always <30°). UtA blood flow velocities were measured online using the software of the ultrasound machine. The uterine artery pulsatility index (UtA PI) was calculated as follows: UtA PI = (peak systolic velocity − end-diastolic velocity)/time-averaged maximum veloc-
ity. An average of three consecutive waveforms was used for analysis.
UtA diameter was measured using power Doppler angiography as described previously. 23, 26, 27 UtA blood flow volume (Quta) was calculated as: Quta = UtA time-averaged intensity weighted mean velocity × cross-sectional area of the UtA. The cross-sectional area was calculated as: 3.14 × (UtA diameter/2). 2 Total Quta was calculated as the sum of the left and the right Quta.
The UtA resistance (Ruta) was calculated as: Ruta = MAP/total Quta. 27 The fraction of maternal CO distributed to the uterus was calculated as total Quta/CO as described previously. Enzyme-linked immunosorbent assay (ELISA) kits were used for quantification of natriuretic peptides according to the manufacturer's instructions. EDTA plasma samples were used for the analysis of proANP and CNP, and BNP was quantified in serum samples.
The intra-assay coefficient of variation (CV) for proANP ELISA kit (EIA-4703, DRG Instruments, GmbH, Marburg, Germany) was ≤5%, the interassay CV ≤9% and sensitivity expressed as limit of detection (LOD) was 0.05 nmol/L (0 pmol/L + 3SD).
Nt-proBNP was quantified using a direct ELISA kit (EIA-4827, DRG Instruments, GmbH) that had an intra-assay CV of ≤4%, an inter-assay CV of ≤7%, sensitivity expressed as LOD was 3 pmol/L (0 pmol/L + 3SD ) and detection range 0-640 pmol/L.
CNP was analyzed using a human C-type natriuretic peptide kit (CSB-E08909h, CUSABIO, Lab-Tech AS, Nesøya, Norway) that had an intra-assay CV of ≤8%, an inter-assay CV of ≤10%, LOD 15.6 pg/mL (0 pg/mL + 3SD) and detection range of 62.5-4000 pg/mL. were not normally distributed, with variables describing maternal cardiac function, systemic hemodynamics and Uta hemodynamics.
| Statistical analyses

| Ethical approval
The study protocol was approved by the Regional Committee 
| RE SULTS
Of a total of 350 pregnant women recruited to the study, three Table 1 . There was no significant difference in maternal age (P = .459) but the HDP group had significantly higher BMI (P = .010) and MAP (P < .001). The HDP group delivered earlier in gestation (P = .008), and had lower birthweight babies (P = .002) with lower 5-minute Apgar scores (P = .001) and lower placental weight (P = .036).
Maternal cardiac function and systemic hemodynamic measurements obtained at baseline and 90 seconds after PLR are shown in Table 2 . At baseline, proANP correlated significantly with CO (r = −.122; P = .023) and LCWI (r = −.112; P = .037). Nt-proBNP correlated significantly with ACI (r = .127; P = .018) and VI (r = −.111; Represents the P value for the difference in percent change between normal and HDP groups (Wilcoxon test or independent sample t test). P = .039). CNP correlated significantly with Quta (r = .118; P = .028)
and Ruta (r = −.112; P = .037) but not with UtA PI (r = .034; P = .523).
During PLR, proANP correlated significantly with Δ% DBP (r = −.124; P = .021), Δ% MAP (r = −.142; P = .008) and Nt-ProBNP correlated significantly with Δ% DBP (r = −.134; P = .013). However, none of the natriutetic peptides correlated significantly with preload reserve.
Women who subsequently developed HDP had significantly higher increase in SV and CO and a greater reduction in SVR following PLR compared with the reference group. ACI, VI and LCWI decreased following PLR in the reference group, whereas they increased in women who later developed HDP.
Maternal UtA hemodynamics and natriuretic peptide levels in the reference group and HDP group are presented in Table 3 . At 22-24 weeks, women who subsequently developed HDP had higher mean UtA PI (1.12 vs .84; P < .001), lower total Quta (552 vs 692 mL/ min; P = .028) and higher Ruta (.28 vs .17 mmHg/mL/min; P = .004) compared with those who did not, but had similar natriuretic peptide levels.
| D ISCUSS I ON
In this study, we evaluated whether there is an association be- Cardiac function is affected by pregnancy due to an increase in preload and a decrease in afterload. These changes are clearly evident by mid-gestation, but the preload reserve, ie, the ability of the heart to increase its output in response to a rapid transient increase in venous return, is limited in the second half of pregnancy, 6,7 most likely due to cardiovascular remodeling as a result of increased volume load. When the heart has adapted to chronic volume load, as in normal pregnancy, there is still a perfect match of afterload with inotropic state, but with essentially maximum use of preload.
Therefore, with limited preload reserve, a mismatch between afterload and inotropic state can happen. As a result, with increasing afterload, the LV may not be able to maintain its SV when preload is fully utilized (ie, the limit of the preload reserve is reached).
30,31
Hameed et al 11 have shown that BNP levels are approximately twofold higher in pregnant women than in non-pregnant women and the levels do not fluctuate significantly. NT-proBNP appears to increase until mid-pregnancy, suggesting a correlation with volume expansion 32 and probably reflecting the physiological increase in CO during pregnancy. However, in our study, the Nt-proBNP levels measured at 22-24 weeks did not correlate with CO; however, ProANP, which is known to increase with myocardial stress, had a negative correlation with CO and LCWI, suggesting that volume overload may negatively affect cardiac performance in pregnancy.
The circulatory volume is usually reduced in women with HDP, and untreated patients with preeclampsia who have increased SVR respond to plasma volume expansion by increasing their CO. 33 In our cohort, women who developed HDP later in gestation, increased their SV and CO, and improved their ICG-derived indices of cardiac contractility during PLR at 22-24 weeks, suggesting that these women might already be slightly volume-depleted in A strength of our study is its relatively large sample size. To our knowledge, this is the largest study so far evaluating maternal cardiac function, using ICG and natriuretic peptides in the same pregnant population. In addition, we studied UtA hemodynamics Although the values of natriuretic peptides are reported to be stable during pregnancy, the cross-sectional design of our study does not allow us to draw conclusions regarding temporal changes in natriuretic peptide levels and their association with maternal functional hemodynamics throughout the pregnancy. Ethnic differences in BNP have been reported in term pregnancies, 12 and as our study population consisted mainly of homogeneous North European women, the findings may not be generalizable to other ethnic populations.
| CON CLUS ION
ProANP correlated with CO and cardiac work, Nt-proBNP with indices of cardiac contractility, and CNP with UtA blood flow and resistance. None of these natriuretic peptides measured at 22-24 weeks of gestation reflected cardiac preload reserve or predicted development of HDP. There appears to be no additional clinical value to measuring natriuretic peptides to screen pregnant women in the second trimester for subsequent development of HDP. However, larger studies are needed to confirm these findings.
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